GlassScriptPhysician profile
Heather Sue Mong
NPI 1831964741
$3,001.79
in general payments reported to CMS, 2019-2025
20 companies · $614 in 2025
The $614 reported for 2025 was more than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $16.37 · 2024: $2,372 · 2025: $614.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,002.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,001.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $556.25 | 2024-2025 | Invega, Spravato |
| Teva Pharmaceuticals USA, INC. | $374.14 | 2024-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Axsome Therapeutics, INC. | $257.61 | 2024-2025 | Auvelity |
| Corium, LLC | $244.58 | 2024-2025 | Azstarys |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $242.40 | 2023-2025 | Caplyta |
| Abbvie INC. | $237.88 | 2024-2025 | |
| Otsuka America Pharmaceutical, INC. | $172.08 | 2024-2025 | Abilify Maintena, Rexulti |
| Lundbeck LLC | $158.29 | 2024-2025 | Rexulti, Brintellix |
| Almatica Pharma LLC | $155.44 | 2024 | Loreev Xr |
| Alkermes, INC. | $154.93 | 2024-2025 | Aristada, Lybalvi, Vivitrol |
| Neurocrine Biosciences, INC. | $131.66 | 2024-2025 | Ingrezza |
| Orexo US, INC. | $64.26 | 2024-2025 | Zubsolv |
| Noven Therapeutics, LLC | $61.25 | 2024-2025 | Xelstrym |
| Indivior INC. | $50.39 | 2024 | Sublocade |
| Sage Therapeutics, LLC | $40.18 | 2024 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tempus Ai, INC | $29.84 | 2024 | |
| Vanda Pharmaceuticals INC. | $20.80 | 2025 | Fanapt, Hetlioz |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $20.00 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $15.60 | 2024 | Trintellix |
| Tris Pharma INC | $14.21 | 2024 | Dyanavel Xr |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Heather Mong listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.